Sobi's partner Biogen submits marketing authorisation application for Alprolix® (rFIXFc) in Europe

10:31 EDT 4 Jun 2015 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix  (rFIXFc)  to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final devel...

Other Sources for this Article


More From BioPortfolio on "Sobi's partner Biogen submits marketing authorisation application for Alprolix® (rFIXFc) in Europe"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Recombinant DNA
Recombinant DNA is the formation of a novel DNA sequence by the formation of two DNA strands. These are taken from two different organisms. These recombinant DNA molecules can be made with recombinant DNA technology. The procedure is to cut the DNA of ...